Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes
<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...
Κύριοι συγγραφείς: | Lotta, LA, Stewart, ID, Sharp, SJ, Day, FR, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, LBL, Kerrison, ND, Khaw, K-T, McCarthy, MI, O'Rahilly, S, Scott, RA, Savage, DB, Perry, JRB, Langenberg, C, Wareham, NJ |
---|---|
Μορφή: | Journal article |
Έκδοση: |
American Medical Association
2018
|
Παρόμοια τεκμήρια
-
Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes
ανά: Lotta, L, κ.ά.
Έκδοση: (2018) -
Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins.
ανά: Sumeet A Khetarpal, κ.ά.
Έκδοση: (2021-09-01) -
Mathematical Modelling of Material Transfer to High-Density Lipoprotein (HDL) upon Triglyceride Lipolysis by Lipoprotein Lipase: Relevance to Cardioprotective Role of HDL
ανά: Svetlana Schekatolina, κ.ά.
Έκδοση: (2022-07-01) -
Human triacylglycerol-rich lipoprotein subfractions as substrates for lipoprotein lipase.
ανά: Fisher, R, κ.ά.
Έκδοση: (1995) -
Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.
ανά: Karpe, F, κ.ά.
Έκδοση: (1993)